

Lasso Grafting

Literature #1

2023/1/26

B4 寺田周平

- Introduction
- Main
 - LassoGraft Technology®
 - Application of LG technology
 - ✓ Addbody®
 - ✓ Mirabody® and other grafted proteins
- Summary


表1 医薬品群の比較

	低分子医薬品	中分子医薬品	高分子医薬品
形態	有機小分子	特殊環状ペプチド	抗体
分子量	500以下	1000～3000	150,000以上
標的特異性	低い	高い	きわめて高い
毒性・副作用	多い	少ない	少ない
経口投与	可能	一部可能	不可能
細胞膜透過性	高い	低い～高い	なし
製造コスト	低い	低い～普通	高い
免疫原性	低い	低い	普通～高い
標的結合面積	狭い	普通～広い	広い
PPI* 阻害	一部可能	可能	可能
生体内安定性	低い～普通	普通～高い	きわめて高い

*PPI：タンパク質間相互作用.

- ✓ Small molecules and macromolecules may have some problems for pharmaceutical use.
- ✓ Macrocyclic peptides has stability in vivo by virtue of its cyclic structure and noncanonical amino acid they composed of.


Phage display




- In vivo translational synthesis
Small library size ($\sim 10^9$)
Toxic peptides cannot be handled because of the use of E. coli.

➤ Simplicity of operation and the size of the library that can be created are important.

OBOC (one-bead-one-compound) display






- Chemical synthesis
Small library size ($\sim 10^7$)




Procedure

1. A DNA library is transcribed → mRNA modified with puromycin → Translated to generate the mRNA–protein fusion.
2. The fusions undergo an experiment-specific selection step.
3. Reverse transcribed into cDNA → Amplified via PCR → Next cycle





- ✓ Flexizyme can incorporate non-canonical amino acids into tRNA.
- ✓ The reconstituted translation system assigns non-normal amino acid-tRNA complexes to codons, allowing for the synthesis of non-natural peptides.

RaPID : Random non-standard Peptide Integrated Discovery



✓ RaPID system makes it possible to find out target-selective cyclic peptide.



- ✓ Peptide grafting can create new functional molecules that combine the functions of peptides and scaffold proteins.
- ✓ Grafting synthetic de novo identified peptides into an independently folded domain of a natural scaffold would often result in the misfolding and inactivation of both entities.

Peptide name	Binding protein (target)	Original RaPID peptide	Sequence used for grafting
PB1m6 ¹	PlxnB1	Ac-wRPRVARWTGQIIYC	WRPRVARWTGQIIY
PB1m6A9 ²	PlxnB1	Ac-wRPYIERWTGRLIVC	WRPYIERWTGRLIV
PB1m7 ¹	PlxnB1	Ac-wNSNVLSWQTYSWYC	(C)NSNVLSWQTYSWY(C)
aMD4 ³	MET	Ac-yRQFNRRTHEVWNLDC	YRQFNRRTHEVWNLD
aMD5 ³	MET	Ac-yWYYAWDQTYKAFPC	YWYYAWDQTYKAFP

By convention, RaPID peptides are cyclized via the *N*-chloroacetyl group of the initiator amino acid and the sulfhydryl group of the terminal Cys. The small letter indicates *D*-amino acids.

PlxnB1; transmembrane receptors for Semaphorins in neural tissues.

MET; hepatocyte growth factor receptor.


✓ From previous studies, the above binding peptides were selected.

1) Matsunaga, Y., *et al. Cell Chem. Biol.*, **2016**, 23(11), 1341-1350.


2) Bashiruddin, N. K., *et al. PNAS.* **2020**, 117(49), 31070-31077.

3) Ito, K., *et al. Nat. Commun.* **2015**, 6(1), 6373.

- Introduction
- Main
 - LassoGraft Technology®
 - Application of LG technology
 - ✓ Addbody®
 - ✓ Mirabody® and other grafted proteins
- Summary




(i) Dimer grafting on uteroglobin (UG)





- ✓ RaPID-derived pharmacophore sequences can be readily implanted into surface-exposed loops on recombinant proteins (LassoGraft Technology[®])
- ✓ Binding affinity of the parental peptide was not lost by dimer grafting.

(ii) loop grafting on proteins


- β -sandwich fold




- β -hairpin




- all- α






- β -barrel



- α/β






M: MET, P: PlxnB1, *: grafted protein
(NR): non-reducing condition, (R): reducing condition

- ✓ Lasso-grafted scaffold proteins retains the binding ability to the proteins on which lasso-grafting peptide targets.

Lasso-grafting on Fc domain




✓ Peptide-grafted Fc protein binding to cell surface target receptors.

✓ The RaPID peptides for many different targets can be readily grafted into various protein scaffolds.

analyte	kinetic constants		
	k_{on} ($\mu\text{M}^{-1}\text{s}^{-1}$)	k_{off} (s^{-1})	K_D (nM)
PB1m6 (free peptide)	3.46	0.012	3.5
PB1m6 (grafted on UG)	0.091	0.0041	45.8
PB1m6A9 (free peptide)	7.59	0.0021	0.28
PB1m6A9 (grafted on UG)	0.17	0.0014	8.26
PB1m6A9 (grafted on Fc)*	18.0	0.0004	0.023
PB1m7 (free peptide)	0.038	0.010	275
PB1m7 (grafted on UG)	0.0158	0.051	3250
PB1m7 (grafted on Fc)*	0.896	0.055	61.4
aMD4 (free peptide)	1.4	0.003	2.4
aMD4 (grafted on UG)	0.044	0.004	91.6
aMD4 (grafted on Fc)*	0.156	0.0007	4.5
aMD5 (free peptide)	4.8	0.011	2.3
aMD5 (grafted on UG)	0.088	0.019	211

(determined using SPR)

Generating multi-specific antibody by Lasso-Grafting



- ✓ By grafting peptides into the Fc domain, multispecificity antibodies were created. <“Addbody®”>
- ✓ Using this method, Addbody-mediated heterotypic cell engagement was achieved.

- Introduction
- Main
 - LassoGraft Technology®
 - Application of LG technology
 - ✓ Addbody®
 - ✓ Mirabody® and other grafted proteins
- Summary

- A tyrosine kinase-type receptor
- Dimerizes and phosphorylates its intracellular domain upon activation by the ligand.
- Met-HGF is centrally involved in morphogenesis during development, wound repair and organ homeostasis
- rHGF has been shown to have therapeutic efficiency.

Short half-life

Poor BBB permeability







図1 HGF-Met シグナリング経路の概念図

Agonist activity of peptide grafted Fc by graft position




- ✓ B3 was the optimal site for aMD4
- ✓ B1 was the optimal site for aMD5.




- ✓ Lasso-grafting into most loops did not affect the affinity of Fc to FcRn.
- ✓ Fc(aMD4)B3 had half-life comparable to that of control Fc.
- ✓ The serum concentration of Fc(aMD4)B3 remained above 1 nM, the minimum concentration for activating Met

Fc(aMD4)B3 acts as an agonist of HGF.




✓ Fc(aMD4)B3 significantly increased replicative DNA synthesis of hepatocytes.
→ Lasso-grafting generated a Met-activating Fc that is bioactive in vivo, with a markedly improved half-life that is comparable to that of unmodified Fc.




- ✓ Via lasso-grafting, Fab affinity was largely preserved.
- ✓ Via lasso-grafting, Met activity was reduced. (due to the bulky Fab)


TfR: トランスフェリン受容体。受容体介在性トランスサイトーシスによりBBBを介した脳内ドラッグデリバリーを行うことができる。



✓ sTfR(aMD4) showed the highest percentage injected dose per gram brain, brain-to-serum ratio, as well as the highest brain concentration .






- ✓ sTfR(aMD4) showed prominent parenchymal staining co-localized with NeuN, GFAP and Iba1, indicating its distribution to neuron, astrocytes and microglia, respectively.



- ✓ Binding to FcRn resulted in a longer half-life.
- ✓ BBB permeability was improved by incorporating TfR.
- Lasso grafting on Fc fragments enhanced pharmacokinetics.

- Introduction
- Main
 - LassoGraft Technology®
 - Application of LG technology
 - ✓ Addbody®
 - ✓ Mirabody® and other grafted proteins
- Summary





Antibody w/o Fab; Mirabody[®] acts as a receptor agonist 26




- ✓ Mirabody[®] acted as the agonist toward PlxnB1.
- ✓ m7-Fc activates receptor dimerization and subsequent signaling.
- ✓ m6A9-Fc acted as antagonist toward PlxnB1 and inhibited Sema4D.
- ✓ It could potentially be biotherapeutics due to the long plasma half-life.

AAV (adeno-associated virus)

- Gene-delivery vehicles
- Broad tropism (Binds to receptors expressed on the surface of many cells)
- Capsid engineering has been used to impart tissue specificity.



✓ By grafting on S2 site, lasso-grafted AAV acquired cell-specific localization.



- ✓ Only viruses expressing a peptide that binds specifically to the receptor could perform gene transfer to cells expressing the receptor protein.
- ✓ Gene transfer efficiency of mutant viruses is higher than that of wild-type viruses.

- Introduction
- Main
 - LassoGraft Technology®
 - Application of LG technology
 - ✓ Addbody®
 - ✓ Mirabody® and other grafted proteins
- Summary

RaPID system

- ✓ Rapid screening of macrocyclic peptides

Lasso-Grafting

- ✓ Functionalization of macrocyclic peptides in vivo
- ✓ Functionalization of host proteins
- ✓ Generation of multispecific antibodies (Addbody®)
- ✓ Improved bioavailability and BBB permeability
- ✓ Generation of receptor agonist/antagonist (Mirabody®)